medigraphic.com

2017, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2017; 55 (5)

Case series of Clostridium difficile NAP1/027/BI with novels treatments

Pérez-Topete SE, Miranda-Aquino T, Ayala-Gaytana JJ

Language: Spanish
References: 22
Page: 654-659
PDF size: 773.54 Kb.


ABSTRACT

Background: Clostridiumdifficile is a spore-forming bacterium, producing exotoxins, causing potentially fatal nosocomial diarrhea. They have recently reported outbreaks of C. difficile ribotype 027, which is characterized by a hypervirulent strain and high resistance to standard therapy.
Clinical case: We present three cases of Clostridium difficile NAP1/027/BI associated infection, they were presented with different clinical manifestations. Two of the patients were successfully treated with the combination of vancomycin plus tigecycline. The other case was treated with fecal microbiota transplant, with resolution of the disease.
Conclusions: in patients with Clostridium difficile NAP1/027/BI associated infection is a good therapeutic option to consider the use of tigecycline in conjunction with vancomycin, as well as fecal microbiota transplantation.


REFERENCES

  1. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile related hospitalizations and case-fatality rate. United States, 2000-2005. Emerg Infect Dis. 2008;14:929-31.

  2. Jalali M, Khorvash F, Warriner K, Weese JS. Clostridium difficile infection in an Iranian hospital. BMC Res Notes. 2012;5:159.

  3. 3 Balassiano IT, Yates EA, Domingues RM, Ferreira EO. Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America. J Med Microbiol. 2012;61:169-79.

  4. Valiente E, Caims MD, Wren BW. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin MIcrobiol Infect. 2014;20:396-404.

  5. McDonald LC, Killgore GE, Thompson A, Owens RC Jr., Kazakova SV, Sambol SP et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.

  6. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.

  7. Remes-Troche JM. Diarrea asociada a infección por Clostridium difficile, es tiempo de preocuparnos en México? Rev Gastroenterol Mex. 2012;77:58-59.

  8. Quesada-Gómez C, Rodriguez C, Gamboa- Coronado M del M, Rodriguez-Cavallini E, Du T, Mulvey MR et al. Emergence of Clostridium difficile NAP1 in Latin America. Journal of Clinical Microbiology. 2010;48:669-670.

  9. Camacho-Ortíz A, López-Barrera D, Hernández- Garcia R, Galván-De los Santos M, Flores-Treviño SM, Llaca-Diaz JM et al. First report of Clostridium difficile NAP/027 in a mexican hospital. PLoS One 2015;10(4):27.

  10. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald MC et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-55.

  11. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults a systematic review. JAMA. 2015;313:98-408.

  12. Ramirez-Rosales A, Cantú-Llanos E. Mortalidad intrahospitalaria en pacientes con diarrea asociada a infección por Clostridium difficile. Rev Gastroenterol Mex. 2012;77:60-65.

  13. Murad YM, Perez J, Nokh Beh R, Ybazeta G, Dewar B, Lefebvre S et al. Impact of polymerasa chain reaction testing on Clostridium difficile infection rates in an acute health care facility. Am J Infect Control. 2015;43:383-386.

  14. Jamal W, Pauline EM, Rotimi VO. Comparative performance of the GeneXpert C. difficile PCR assay and C. difficile Quik Chek complete kit assay fir the detection of Clostridium difficile antigen and toxins in symptomatic community-onset infections. Intern Jour Infect Dis. 2014;29:244-248.

  15. Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World Surg Emerg Surg. 2015;10:38.

  16. Di Bella S, Nisii C, Petrosillo N. Is tigecycline a suitable option for Clostridium difficile infection? Evidence for the literature. Intern Jour Antimicrob Agents. 2015,46:8-12.

  17. Aldape MJ, Heeney DD, Bryant AE, Stevens DL. Tigecycline suppresses toxin A and B and sporulation in Clostridium difficile. J Antimicrob Chemother. 2015;70:153-159.

  18. Van Nood E, Vrieza A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.

  19. Kelly CP. Fecal microbiota transplantation- An old therapy comes of age. N Engl J Med. 2013;368:474-475.

  20. Hernández-Rocha C, Barra-Carrasco J, Pizarro- Guajardo M, Ibanez P, Bueno SM, Sarker MR et al. Epidemic Clostridium difficile ribotype 027 in Chile. Emerg Infect Dis. 2012;18:1370-1372.

  21. Aguayo C, Flores R, Lévesque S, Araya P, Ulloa S, Lagos J et al. Rapid spread of Clostridium difficile NAP1/027/ST1 in Chile confirms the emergence of the epidemic strain in Latin America. Epidemiol Infect. 2015;143:3069-3073.

  22. Morfin-Otero R, Garza-González E, Aguirre-Díaz SA, Escobedo-Sánchez R, Esparza-Ahumada S, Perez-Gómez HR et al. Clostridium difficile outbreak caused by NAP1/BI/027 strain and non- 027 strains in a Mexican hospital. Braz J Infect Dis. 2016;20(1):8-13.




2020     |     www.medigraphic.com